300 related articles for article (PubMed ID: 17805486)
1. Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
Esteban E; Villanueva N; Muñiz I; Fernández Y; Fra J; Luque M; Jiménez P; Llorente B; Capelan M; Vieitez JM; Estrada E; Buesa JM; Jiménez-Lacave A
Invest New Drugs; 2008 Feb; 26(1):67-74. PubMed ID: 17805486
[TBL] [Abstract][Full Text] [Related]
2. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
Georgoulias V; Ardavanis A; Tsiafaki X; Agelidou A; Mixalopoulou P; Anagnostopoulou O; Ziotopoulos P; Toubis M; Syrigos K; Samaras N; Polyzos A; Christou A; Kakolyris S; Kouroussis C; Androulakis N; Samonis G; Chatzidaki D
J Clin Oncol; 2005 May; 23(13):2937-45. PubMed ID: 15728228
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Pujol JL; Breton JL; Gervais R; Rebattu P; Depierre A; Morère JF; Milleron B; Debieuvre D; Castéra D; Souquet PJ; Moro-Sibilot D; Lemarié E; Kessler R; Janicot H; Braun D; Spaeth D; Quantin X; Clary C
Ann Oncol; 2005 Apr; 16(4):602-10. PubMed ID: 15741225
[TBL] [Abstract][Full Text] [Related]
4. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study.
Esteban E; Fra J; Fernández Y; Corral N; Vieitez JM; Palacio I; de Sande JL; Fernández JL; Muñiz I; Villanueva N; Estrada E; Mareque B; Uña E; Buesa JM; Lacave AJ;
Invest New Drugs; 2006 May; 24(3):241-8. PubMed ID: 16096704
[TBL] [Abstract][Full Text] [Related]
8. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Alberola V; Camps C; Provencio M; Isla D; Rosell R; Vadell C; Bover I; Ruiz-Casado A; Azagra P; Jiménez U; González-Larriba JL; Diz P; Cardenal F; Artal A; Carrato A; Morales S; Sanchez JJ; de las Peñas R; Felip E; López-Vivanco G;
J Clin Oncol; 2003 Sep; 21(17):3207-13. PubMed ID: 12947054
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer.
Ando S; Suzuki M; Iida T; Nakajima T; Kimura H
Oncol Rep; 2005 Sep; 14(3):689-94. PubMed ID: 16077976
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
Han JY; Lee DH; Song JE; Lee SY; Kim HY; Kim HT; Lee JS
Cancer; 2008 Jul; 113(2):388-95. PubMed ID: 18484595
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
Saito H; Nakagawa K; Takeda K; Iwamoto Y; Ando M; Maeda M; Katakami N; Nakano T; Kurata T; Fukuoka M
Am J Clin Oncol; 2012 Feb; 35(1):58-63. PubMed ID: 21293243
[TBL] [Abstract][Full Text] [Related]
13. Alternating doublets: establishing the optimal multifractionated dosing schedule to administer docetaxel, cisplatin, gemcitabine, and vinorelbine in combination.
Lokich J; Anderson N; Coco F
Cancer Invest; 2003; 21(6):830-6. PubMed ID: 14735686
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.
Yamamoto N; Nakagawa K; Uejima H; Sugiura T; Takada Y; Negoro S; Matsui K; Kashii T; Takada M; Nakanishi Y; Kato T; Fukuoka M;
Cancer; 2006 Aug; 107(3):599-605. PubMed ID: 16804877
[TBL] [Abstract][Full Text] [Related]
15. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.
Laack E; Dickgreber N; Müller T; Knuth A; Benk J; Lorenz C; Gieseler F; Dürk H; Engel-Riedel W; Dalhoff K; Kortsik C; Graeven U; Burk M; Dierlamm T; Welte T; Burkholder I; Edler L; Hossfeld DK;
J Clin Oncol; 2004 Jun; 22(12):2348-56. PubMed ID: 15197195
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC
Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience.
Tada H; Matsui S; Kawahara M; Hosoe S; Hamada C; Fukushima M
Eur J Cancer Care (Engl); 2008 Mar; 17(2):120-6. PubMed ID: 18302648
[TBL] [Abstract][Full Text] [Related]
19. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
[TBL] [Abstract][Full Text] [Related]
20. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Georgoulias V; Scagliotti G; Miller V; Eckardt J; Douillard JY; Manegold C
Semin Oncol; 2001 Feb; 28(1 Suppl 2):15-21. PubMed ID: 11284620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
